Jaguar Health Inc. (JAGX)
Jaguar Health Statistics
Share Statistics
Jaguar Health has 16.32M shares outstanding. The number of shares has increased by -94.29% in one year.
Shares Outstanding | 16.32M |
Shares Change (YoY) | -94.29% |
Shares Change (QoQ) | 27.67% |
Owned by Institutions (%) | 0% |
Shares Floating | 12.45M |
Failed to Deliver (FTD) Shares | 7.08K |
FTD / Avg. Volume | 1.45% |
Short Selling Information
The latest short interest is 332.32K, so 2.82% of the outstanding shares have been sold short.
Short Interest | 332.32K |
Short % of Shares Out | 2.82% |
Short % of Float | 3.23% |
Short Ratio (days to cover) | 1.12 |
Valuation Ratios
The PE ratio is -0.03 and the forward PE ratio is -0.46. Jaguar Health's PEG ratio is 0.
PE Ratio | -0.03 |
Forward PE | -0.46 |
PS Ratio | 0.12 |
Forward PS | 0.4 |
PB Ratio | 0.23 |
P/FCF Ratio | -0.04 |
PEG Ratio | 0 |
Enterprise Valuation
Jaguar Health Inc. has an Enterprise Value (EV) of 34.12M.
EV / Earnings | -0.83 |
EV / Sales | 3.5 |
EV / EBITDA | -1.03 |
EV / EBIT | -0.99 |
EV / FCF | -1.03 |
Financial Position
The company has a current ratio of 2, with a Debt / Equity ratio of 7.48.
Current Ratio | 2 |
Quick Ratio | 1.34 |
Debt / Equity | 7.48 |
Total Debt / Capitalization | 88.2 |
Cash Flow / Debt | -0.9 |
Interest Coverage | -5.37 |
Financial Efficiency
Return on equity (ROE) is -8.32% and return on capital (ROIC) is -81.66%.
Return on Equity (ROE) | -8.32% |
Return on Assets (ROA) | -0.81% |
Return on Capital (ROIC) | -81.66% |
Revenue Per Employee | 199.2K |
Profits Per Employee | -842.86K |
Employee Count | 49 |
Asset Turnover | 0.19 |
Inventory Turnover | 0.22 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -65.54% in the last 52 weeks. The beta is 0.85, so Jaguar Health's price volatility has been higher than the market average.
Beta | 0.85 |
52-Week Price Change | -65.54% |
50-Day Moving Average | 0.91 |
200-Day Moving Average | 1.25 |
Relative Strength Index (RSI) | 33.81 |
Average Volume (20 Days) | 487.79K |
Income Statement
In the last 12 months, Jaguar Health had revenue of 9.76M and earned -41.3M in profits. Earnings per share was -107.42.
Revenue | 9.76M |
Gross Profit | 7.72M |
Operating Income | -34.29M |
Net Income | -41.3M |
EBITDA | -33.13M |
EBIT | -34.29M |
Earnings Per Share (EPS) | -107.42 |
Balance Sheet
The company has 6.47M in cash and 37.09M in debt, giving a net cash position of -30.63M.
Cash & Cash Equivalents | 6.47M |
Total Debt | 37.09M |
Net Cash | -30.63M |
Retained Earnings | -308.25M |
Total Assets | 58.47M |
Working Capital | 16.77M |
Cash Flow
In the last 12 months, operating cash flow was -33.24M and capital expenditures 0, giving a free cash flow of -33.24M.
Operating Cash Flow | -33.24M |
Capital Expenditures | 0 |
Free Cash Flow | -33.24M |
FCF Per Share | -86.46 |
Margins
Gross margin is 79.13%, with operating and profit margins of -351.31% and -423.11%.
Gross Margin | 79.13% |
Operating Margin | -351.31% |
Pretax Margin | -429.27% |
Profit Margin | -423.11% |
EBITDA Margin | -339.42% |
EBIT Margin | -351.31% |
FCF Margin | -340.56% |
Dividends & Yields
JAGX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -17609.84% |
FCF Yield | -333.98% |
Analyst Forecast
Currently there are no analyst rating for JAGX.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Stock Splits
The last stock split was on May 23, 2024. It was a backward split with a ratio of 1:60.
Last Split Date | May 23, 2024 |
Split Type | backward |
Split Ratio | 1:60 |
Scores
Altman Z-Score | -9.21 |
Piotroski F-Score | 5 |